Article Text

PDF
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis
  1. S Joossens1,
  2. J-F Colombel2,
  3. C Landers3,
  4. D Poulain4,
  5. K Geboes5,
  6. X Bossuyt6,
  7. S Targan7,
  8. P Rutgeerts8,
  9. W Reinisch9
  1. 1Departments of Gastroenterology, University Hospital Gasthuisberg Leuven, Belgium
  2. 2Department of Gastroenterology, CHRU Lille, France
  3. 3Cedars-Sinai IBD Center, Los Angeles, California, USA
  4. 4Department of Laboratory of Parasitology-Mycology, CHRU Lille, France
  5. 5Departments of Pathology, University Hospital Gasthuisberg Leuven, Belgium
  6. 6Laboratory Medicine Immunology, University Hospital Gasthuisberg Leuven, Belgium
  7. 7Cedars-Sinai IBD Center, Los Angeles, California, USA
  8. 8Departments of Gastroenterology, University Hospital Gasthuisberg Leuven, Belgium
  9. 9Department of Gastroenterology and Hepatology, University of Vienna, Austria
  1. Correspondence to:
    MsS Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Belgium; sofie.joossens{at}uz.kuleuven.ac.be

Statistics from Altmetric.com

In a previous prospective study on the diagnostic value of serological markers in patients with indeterminate colitis (IC), we demonstrated that those who remained classified as IC during prospective follow up were more often negative for anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (pANCA) compared with patients with an eventual diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC).1 New antibodies directed against luminal bacterial components have been reported in inflammatory bowel disease. Anti-OmpC IgA (directed against outer membrane porin C of E coli) and anti-I2 (directed against Pseudomonas fluorescens) have both been found in approximately 50% of CD patients2–4 and are both associated with ileal disease, increasing disease duration, and more severe disease that requires small bowel surgery.5,6

We investigated if anti-OmpC and anti-I2 were additive to ASCA and pANCA in the definitive diagnosis of patients who were included in our initial cohort of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.